Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald speaks to Proactive's Thomas Warner after announcing the creation of a scientific advisory board.
Reginald explains the rationale for the decision, before going to explain what each of the three-strong team will bring to Roquefort as it heads toward what he calls “key pre-clinical milestones”.